Mylan, Akorn, Astex Pharma, and Forest Laboratories Under StockCall's Microscope
* Reuters is not responsible for the content in this press release.
For best results when printing this announcement, please click on the link below: http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130408:nPn4089230 LONDON, April 8, 2013 /PRNewswire/ -- A major trend to emerge in the healthcare industry since last year has been the expiration of patents on several blockbuster drugs. The trend has benefited companies such as Mylan Inc. (NASDAQ: MYL), and Akorn Inc. (NASDAQ: AKRX), which focus generic drugs. For major drug manufacturers such as Astex Pharmaceuticals Inc. (NASDAQ: ASTX), and biotechnology companies such as Forest Laboratories Inc. (NYSE: FRX), increasing generic competition is a major concern. Meanwhile, the healthcare industry is also evaluating the impact of President Obama's Affordable Care Act (ACA), which was upheld by the Supreme Court last year. Healthcare stocks ended on a mixed note on Friday as the broad market struggled following dismal jobs report for the month of March. StockCall has released full comprehensive research on MYL, AKRX, ASTX, and FRX and these free technical analyses can be downloaded by signing up at http://www.stockcall.com/technicalanalysis Shares of Mylan Inc. ended nearly flat in Friday's trading session. The stock traded between $28.20 and $28.66 before finishing the day 0.03% lower at $28.63. Mylan's shares have had a decent run so far in 2013, gaining more than 4%. However, the stock has struggled in the last two weeks after failing to break through $31 resistance level. The company's shares have seen a series of lows over the past two weeks, which is a bearish signal. The downbeat trend is further confirmed by the stock's MACD chart. The stock has also slipped below its 50-day moving average. Free technical analysis on MYL available by signing up at http://www.StockCall.com/MYL040813.pdf Akorn Inc.'s shares ended flat in Friday's trading session. The stock traded between $13.25 and $13.51 before finishing the day at $13.50. Akorn's shares last week slipped below their 200-day moving average, which is a bearish signal. The stock's MACD has also slipped below the signal line, further confirming the negative trend. The company's shares currently have support at around $13.25. Year-to-date, the stock has gained more than 1%. Register today and access the free research on AKRX at http://www.StockCall.com/AKRX040813.pdf Shares of Astex Pharmaceuticals Inc. rose sharply in trading on Friday even as the broad market struggled. The stock touched an intra-day high of $5.49 before finishing the day 3.06% higher at $5.39. Astex Pharma's shares are currently trading close to their 52-week high of $5.81. The stock has gained more than 6.70% in the last three sessions. Year-to-date, the company's shares have gained more than 85%, easily outperforming the broad market. The stock has seen a series of highs over the past two weeks, which is a bullish signal. The free report on ASTX can be downloaded by signing up now at http://www.StockCall.com/ASTX040813.pdf Shares of Forest Laboratories Inc. edged lower on Friday, tracking losses in the broad market. The stock ended the day 0.37% lower at $37.52 after touching an intra-day low of $37.08. Shares of FRX have traded sideways in the last few weeks, struggling to break through $38 resistance level. The stock is currently trading above its 50-day and 200-day moving averages, which is a bullish signal. However, the stock's MACD chart suggests that market sentiment has turned bearish. Year-to-date, the stock has gained more than 6.20%. Free report on FRX can be accessed by registering at http://www.StockCall.com/FRX040813.pdf About StockCall.com StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at http://www.stockcall.com SOURCE StockCall.com Contact Person: William T. Knight, Email: firstname.lastname@example.org, Contact Number: +1(646) 396-9857 (9:00 am EST - 01:30 pm EST)
- California passes 'yes-means-yes' campus sexual assault bill
- Ukraine seeks to join NATO; defiant Putin compares Kiev to Nazis |
- In town halls, U.S. lawmakers hear voter anger over illegal migrants |
- IBM launches Watson system for research, hopes for breakthroughs
- U.N. says 43 Golan peacekeepers seized by Syria militants, 81 trapped